Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To demonstrate progression free survival (PFS) improvement for cabazitaxel compared to
topotecan in participants with sensitive or resistant/refractory small cell lung cancer
following a first line platinum based chemotherapy.
Secondary Objectives:
- To assess disease progression free rate at 12 weeks
- To assess Response Rate (Response Evaluation Criteria in Solid Tumor [RECIST] 1.1) and
duration of response
- To assess Overall Survival (OS)
- To assess the Safety (National Cancer Institute - Common Toxicity Criteria [NCI-CTC]
version 4.03)
- To assess the Health-Related Quality of Life (HRQoL)